2nd Quarter - Report

AVANIR PHARMACEUTICALS for AVANIR PHARMACEUTICALS

Firm
Client
Income
—
Expenses
$90,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act. H.R. 19, S. 2164, Lower Cost More Cures Act of 2021. H.R. 5376, Build Back Better Act, specifically issues dealing with Medicare.

LobbyistCovered position, as disclosed
CATHERINE DRATZ FERGUSON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 19 (117th), H.R. 5376 (117th), H.R. 3 (117th), S. 2164 (117th)

Health Issues HCR

H.R.7667 - Food and Drug Amendments of 2022, specifically provisions regarding the Prescription Drug User Fee Act (PDUFA). Issue related to mental health.

LobbyistCovered position, as disclosed
CATHERINE DRATZ FERGUSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 7667 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.